29 April 2021 - final results

Final results for the year ended 31 December 2020 have been released by the AIM-listed specialist drug discovery and development company.  The figures are largely irrelevant given the stage of the company's development but for the record, revenue remained negligible and the loss before tax widened from £6.7m to £7.2m.  Of greater importance, cash held at the period end was £5.9m.  Three successful capital raisings mean there is sufficient cash to last until the end of 2023.  The company remains focused, in collaboration with its partner Avion, on expediting Lupuzor . . .

This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.

Already a member, log in HERE.